AHA yesterday commented on recent Medicare Payment Advisory Commission discussions on possible approaches to reducing spending on Part B drugs and biologicals, improving alternative payment models, and revising the hospital wage index. The letter raises concerns with approaches that would shift responsibility for surging drug prices from drug manufacturers to hospitals and patients. Instead, it supports a cap on average sales price inflation that requires drug manufacturers to pay rebates to the federal government when ASP growth exceeds an inflation benchmark, and encourages the commission to further evaluate a payment model that implements mandatory additional rebates to purchasers when the manufacturer’s price increase for a Part B drug exceeds inflation. The letter also raises concerns with possible approaches that would use non-hospital data to calculate the wage index. In addition, AHA voiced support for exploring how a multi-track APM could “provide a glide path to risk for all potential participants” to ensure “a balance between incentivizing participation in models and securing cost savings and high-quality care for patients.” 

Related News Articles

Headline
The Senate Committee on Health, Education, Labor and Pensions Oct. 23 held a hearing discussing the 340B Drug Pricing Program and its growth and impacts on…
Headline
The AHA Oct. 23 recommended changes to the Centers for Medicare & Medicaid Services’ Wasteful and Inappropriate Services Reduction model to address…
Headline
The Centers for Medicare & Medicaid Services has released an operational guide for Medicare-enrolled providers and suppliers on the Wasteful and…
Headline
A report by the Department of Health and Human Services Office of the Inspector General found that many Medicare Advantage and Medicaid managed care plans…
Headline
Medicare open enrollment for 2026 began Oct. 15 and runs through Dec. 7. During the annual enrollment period, Medicare-eligible individuals can check their…
Headline
The AHA Oct. 3 responded to the Medicare Payment Advisory Commission’s recent analysis on the financial impacts of Medicare Advantage enrollment growth on…